Press-release for stocks related to cancer for eli lilly and company

tags : Cancer entities : Eli lilly and company

save search

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| -3.34% | O: -2.79% H: 1.32% C: 1.18%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -5.44% | O: -1.14% H: 0.02% C: -1.06%
review cancer treatment advanced china

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -6.28% | O: 1.06% H: 0.0% C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M

Health Technology

| -6.77% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| -2.86% | O: -100.0% H: NaN% C: Infinity%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -3.27% | O: -0.08% H: 0.15% C: -0.44%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| -2.57% | O: 0.06% H: 0.96% C: 0.26%
CAH | $106.0 -0.49% -0.94% 1.5M

Distribution Services

| -3.46% | O: 0.02% H: 0.73% C: -0.02%
LNTH | News | $62.34 1.4% 1.38% 1.3M

Health Technology

| 4.17% | O: 0.1% H: 1.98% C: -0.08%
reach cancer treatment market

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| -3.45% | O: 0.86% H: 0.45% C: -0.58%
association cancer research meeting

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $140.15 -4.19% 560

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.16 0.08% 0.0% 1.3M

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.3 0.96% -0.1% 11M

Health Technology

| -5.21% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -7.04% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -2.16% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $262.77 -0.49% -0.49% 2M

Health Technology

| -5.83% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -7.04% | O: 1.47% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.3 0.96% -0.1% 11M

Health Technology

| -2.03% | O: -0.14% H: 0.35% C: -1.12%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -4.15% | O: 1.48% H: 0.0% C: 0.0%
VRTX | News | $393.51 0.1% 0.1% 950K

Health Technology

| -5.53% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -0.9% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | $109.3 2.05% 2.01% 560K

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $262.77 -0.49% -0.49% 2M

Health Technology

| -15.55% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 21.54% | O: 1.22% H: 1.78% C: -1.72%
merck cancer agreement

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -7.46% | O: -1.87% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 31.67% | O: 0.21% H: 0.63% C: 0.1%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -5.45% | O: -0.08% H: 0.0% C: 0.0%
cancer growth study market

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0

| -9.84% | O: -10.09% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 32.34% | O: 1.61% H: 1.14% C: 0.57%
LNTH | News | $62.34 1.4% 1.38% 1.3M

Health Technology

| -19.15% | O: -19.87% H: 5.04% C: -8.75%
positive cancer biopharma topline trial results

Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -3.35% | O: 0.25% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 28.73% | O: 1.8% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -4.53% | O: 0.0% H: 0.0% C: 0.0%
positive cancer growth study market

Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
Published: 2023-12-12 (Crawled : 22:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 25.42% | O: -2.88% H: 0.0% C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K

Health Technology

| 26.11% | O: 0.21% H: 1.18% C: 0.43%
breast life cancer pharmaceuticals results

Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 27.54% | O: -0.35% H: 0.0% C: 0.0%
cancer study market

Metastatic Non-small Cell Lung Cancer Market Forecast Analysis and with Focus on its Immune/Molecular Biomarker Types: PD-L1, EGFR, KRAS, ALK, BRAF, MET, ROS-1, HER2, RET fusion, and NTRK1/2/3 Gene fusion | DelveInsight
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -4.39% | O: -0.04% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 26.85% | O: -0.06% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -1.85% | O: -0.15% H: 0.07% C: -0.66%
BPMC | News | $88.9 0.59% 0.58% 730K

Health Technology

| 25.92% | O: 0.5% H: 1.86% C: -0.33%
lung biomarker cancer cell market

Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 15:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 26.92% | O: 0.05% H: 0.0% C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K

Health Technology

| 33.66% | O: 0.49% H: 0.83% C: -2.14%
breast symposium presentation cancer pharmaceuticals

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 28.02% | O: -1.68% H: 0.0% C: 0.0%
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 60.71% | O: 0.0% H: 7.14% C: -5.36%
candidate symposium cancer protein therapeutics molecular

Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| Email alert Add to watchlist
retevmo lung congress symposium cancer cell thyroid results

Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
Published: 2023-10-20 (Crawled : 12:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 25.11% | O: -1.52% H: 0.0% C: 0.0%
verzenio breast cancer impact

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.51 -6.63% -7.1% 470K

Professional, Scientific, and T...

| 147.69% | O: 0.0% H: 2.56% C: 2.56%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 23.38% | O: 1.15% H: 0.0% C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -40.22% | O: -1.63% H: 4.97% C: 2.76%
MRUS | $40.41 -1.56% -1.58% 240K

Health Technology

| 94.73% | O: 0.47% H: 1.7% C: -0.38%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| 0.23% | O: -0.59% H: 0.62% C: -0.56%
fda year review cancer pancreatic

Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo
Published: 2023-10-04 (Crawled : 21:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 43.21% | O: 1.72% H: 0.0% C: 0.0%
RVMD S | $35.81 -2.74% -2.82% 1M

Health Technology

| 51.27% | O: -0.58% H: 4.83% C: 4.38%
IOVA M | $11.72 -0.68% -0.68% 3.6M

Health Technology

| 188.51% | O: 0.24% H: 3.66% C: 1.95%
BNTX | $86.19 -0.24% -0.24% 580K

Health Technology

| -21.68% | O: -0.44% H: 1.52% C: 0.08%
AXSM | $65.81 -5.6% -5.93% 830K

Health Technology

| 6.5% | O: -0.43% H: 4.97% C: 4.71%
lung companies cancer study market

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-10-04 (Crawled : 16:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 39.79% | O: -2.39% H: 0.0% C: 0.0%
conference cancer international therapeutics molecular

← Previous
1
2
3
4
5
6
7
Next →

tags : Cancer entities : Eli lilly and company

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer entities : Eli lilly and company save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

tags : Cancer entities : Eli lilly and company

save search